Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, especially in fashion and apparel which accounts for over 62% of the market share. E-commerce expansion and domestic travel boost demand for casual and resort wear, while government incentives encourage efficiency improvements. However, competition from cheaper imports and skilled labor costs may limit large-scale expansion, prompting targeted upgrades and cost-effective operations.
The textile industry in Thailand is projected to grow to USD 5.39 billion by 2032, with fashion and apparel holding a 62.58% market share in 2026. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 02, 2026 20:13 WIB: out of 134 priced US stocks, 98 rose and 18 fell. Notable movers include Alibaba Group (BABA) at USD 101.58 with a +3.68% change and a typical hold time of 114 days, Norwegian Cruise Line Holdings Ltd (NCLH) at USD 18.07 with a +2.82% change and a typical hold time of 69 days, and Aterian Inc (ATER) at USD 0.75 with a -2.76% change and a typical hold time of 27 days.
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
